DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



CKD-330 Drug-Drug Interaction Study (Candesartan)

Information source: Chong Kun Dang Pharmaceutical
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Candesartan 32mg (Drug); Candesartan 32mg/Amlodipine 10mg (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Chong Kun Dang Pharmaceutical

Official(s) and/or principal investigator(s):
Kyun-Seop Bae, Professor, Principal Investigator, Affiliation: Asan Medical Center

Summary

The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety of Candesartan between free combination of Candesartan and Amlodipine and Candesartan monotherapy.

Clinical Details

Official title: A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Candesartan Between Free Combination of Candesartan and Amlodipine and Candesartan Monotherapy in Healthy Male Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

AUCτ,ss of Candesartan

Cmax,ss of Candesartan

Secondary outcome: Tmax,ss of Candesartan

Eligibility

Minimum age: 20 Years. Maximum age: 45 Years. Gender(s): Male.

Criteria:

Inclusion Criteria: 1. Healthy male volunteer is between 20 and 45 years of age(inclusive) at the pre-study(screening). 2. Volunteer who has 19kg/m² ≤ BMI(Body Mass Index) ≤ 26kg/m² 3. When volunteer in screening, Must include under the items. 1. 100 mmHg ≤ sitting SBP <140 mmHg 2. 60 mmHg ≤ sitting DBP < 90 mmHg 3. 45 bpm ≤ Pulse < 95 bpm 4. Those who decided to join the clinical trials by themselves and to comply with the precautions written consent. Exclusion Criteria: 1. A previous history or present of clinically significant liver, renal, gastro-intestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hemato-oncological, cardiovascular disease. 2. Have a gastrointestinal disease history that can affect drug absorption(Crohn's disease, Ulcers, GERD, Gastritis, etc.) or surgery (except simple appendectomy or hernia surgery). 3. The history of clinically significant hypersensitivity reaction about Investigational drugs and foods. 4. The history of drug abuse or drug abuse showed a positive for urine drug test. 5. Taking drugs have received any other investigational drug within 90 days prior to the first dosing and metabolizing enzyme inducers or inhibitors such as barbitals within 30 days prior to the first dosing. 6. Whole blood donation within 60 days prior to the first dosing or plasma donation within 30 days prior to the first dosing. 7. Taking drugs that clinical trials expected to affect within 14days or taking food containing caffeine, grapefruit within 7days before the first dosing. 8. A heavy alcohol consumer(alcohol>3cup/day or 3times/week within last 1month) 9. A heavy smoker(cigarette>10cigarettes/day) 10. The subject has positive results of serum tests(Hepatitis B, C, HIV Test, Syphilis). 11. Have the Liver enzyme levels(AST, ALT) or Bilirubin, total results greater than 1. 5 times the UNL. 12. Have the result of Creatinine clearance is less than 80mL/min(Cockcroft-Gault equation applicable). 13. The result of 12-lead ECG in screening test is QTc>450msec. 14. An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.

Locations and Contacts

Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
Additional Information

Starting date: June 2014
Last updated: September 1, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017